Cytokinetics is approaching its first regulatory approval after nearly 30 years in business as it positions aficamten, an oral therapy for obstructive cardiomyopathy, for market entry. Wall Street models aficamten as a potential blockbuster and the company is gearing up for competitive friction with large cardiovascular players, notably Bristol Myers Squibb. Management has been preparing commercialization efforts and regulatory engagements ahead of an imminent approval date. The program’s success would mark a material shift for Cytokinetics — from long‑running development-stage biotech to marketed‑product company — and set the stage for forthcoming commercial and payer negotiations.